AR090245A1 - Preparacion solida oral de liberacion sostenida, metodo de preparacion - Google Patents
Preparacion solida oral de liberacion sostenida, metodo de preparacionInfo
- Publication number
- AR090245A1 AR090245A1 ARP130100712A ARP130100712A AR090245A1 AR 090245 A1 AR090245 A1 AR 090245A1 AR P130100712 A ARP130100712 A AR P130100712A AR P130100712 A ARP130100712 A AR P130100712A AR 090245 A1 AR090245 A1 AR 090245A1
- Authority
- AR
- Argentina
- Prior art keywords
- sustained release
- gum
- gelling agent
- ratio
- weight
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 8
- 238000013268 sustained release Methods 0.000 title abstract 8
- 239000012730 sustained-release form Substances 0.000 title abstract 8
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000003349 gelling agent Substances 0.000 abstract 9
- 239000003405 delayed action preparation Substances 0.000 abstract 6
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 6
- 229920000161 Locust bean gum Polymers 0.000 abstract 5
- 239000000711 locust bean gum Substances 0.000 abstract 5
- 235000010420 locust bean gum Nutrition 0.000 abstract 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 4
- 229960004372 aripiprazole Drugs 0.000 abstract 4
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000005846 sugar alcohols Polymers 0.000 abstract 4
- 125000002091 cationic group Chemical group 0.000 abstract 2
- 238000004132 cross linking Methods 0.000 abstract 2
- 239000003431 cross linking reagent Substances 0.000 abstract 2
- 150000002016 disaccharides Chemical class 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000002772 monosaccharides Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 150000001342 alkaline earth metals Chemical class 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Una preparación sólida oral de liberación sostenida que comprende aripiprazol o una sal del mismo, como un ingrediente activo, y un método para producir la preparación sólida oral de liberación sostenida. Una preparación sólida oral de liberación sostenida comprende aripiprazol o una sal del mismo y un excipiente de liberación sostenida; el excipiente de liberación sostenida comprende: un gelificante; al menos un diluyente farmacéutico inerte, seleccionado del grupo que consiste en monosacáridos, disacáridos, alcoholes polihídricos y mezclas de los mismos y un agente de entrecruzamiento catiónico farmacéuticamente aceptable, capaz de entrecruzarse con el gelificante y de incrementar la resistencia del gel cuando la preparación sólida oral de liberación sostenida se expone a un fluido del ambiente, donde el gelificante comprende goma xantánica y goma de algarrobilla, donde la relación de la goma xantánica a la goma de algarrobilla en el gelificante es de aproximadamente 1:1 a 1:3 en peso, la relación del diluyente farmacéutico inerte al gelificante es de aproximadamente 1:1 a 1:2 en peso. Reivindicación 1: Una preparación sólida oral de liberación sostenida que comprende aripiprazol o una sal del mismo, y un excipiente de liberación sostenida, donde e excipiente de liberación, sostenida comprende: un gelificante que comprende goma xantánica y goma de algarrobilla; al menos un diluyente farmacéutico inerte seleccionado del grupo que consiste en monosacáridos, disacáridos, alcoholes polihídricos y mezclas de los mismos; y un agente de entrecruzamiento catiónico farmacéuticamente aceptable, capaz de entrecruzarse con el gelificante y de incrementar la resistencia del gel cuando la preparación sólida oral de liberación sostenida se expone a un fluido del ambiente, donde la relación de la goma xantánica a la goma de algarrobilla en el gelificantes es de aproximadamente 1:1 a 1:3 en peso, donde la relación del diluyente farmacéutico inerte al gelificante es de aproximadamente 1:1 a 1:2 en peso. Reivindicación 5: Una preparación sólida oral de liberación sostenida que comprende aripiprazol o una sal del mismo, y un excipiente e liberación sostenida, donde el excipiente de liberación sostenida comprende: una goma que comprende un combinación de goma xantánica con goma de allgarrobilla; un alcohol de azúcar; y una sal orgánica o inorgánica de un metal alcalino y/o un metal alcalinotérreo, donde la relación de la goma xantánica a la goma de algarrobilla es de aproximadamente 1:1 a 1:3 en peso y donde la relación del alcohol de azúcar a la goma se encuentra dentro del rango variable entre alrededor de 1:1 y 1:2 en peso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607291P | 2012-03-06 | 2012-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090245A1 true AR090245A1 (es) | 2014-10-29 |
Family
ID=48014240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100712A AR090245A1 (es) | 2012-03-06 | 2013-03-05 | Preparacion solida oral de liberacion sostenida, metodo de preparacion |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20150037424A1 (es) |
| EP (1) | EP2822989A1 (es) |
| JP (1) | JP2015509482A (es) |
| KR (1) | KR20140131987A (es) |
| CN (1) | CN104159949A (es) |
| AR (1) | AR090245A1 (es) |
| AU (1) | AU2013228315A1 (es) |
| CA (1) | CA2865882A1 (es) |
| CO (1) | CO7091180A2 (es) |
| EA (1) | EA201491640A1 (es) |
| HK (1) | HK1200738A1 (es) |
| IN (1) | IN2014DN06939A (es) |
| MX (1) | MX2014010574A (es) |
| PH (1) | PH12014501853A1 (es) |
| SG (1) | SG11201404915SA (es) |
| TW (1) | TW201343201A (es) |
| WO (1) | WO2013133448A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JP2018174986A (ja) * | 2017-04-03 | 2018-11-15 | 花王株式会社 | 吸収構造体及びそれを備えた吸収性物品 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| JP4170032B2 (ja) | 2002-07-12 | 2008-10-22 | 本多通信工業株式会社 | 光分岐器及びｏ／ｅ変換コネクタ |
| US20060193912A1 (en) * | 2005-02-28 | 2006-08-31 | Penwest Pharmaceuticals Co. | Controlled release O-desmethylvenlafaxine formulations |
| EP2079453A1 (en) | 2006-10-10 | 2009-07-22 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
| WO2009108077A2 (en) * | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| WO2010079506A2 (en) * | 2008-06-23 | 2010-07-15 | Torrent Pharmaceuticals Ltd. | Pharmaceutical composition of aripiprazole |
| US20120214820A1 (en) * | 2009-09-15 | 2012-08-23 | Ratiopharm Gmbh | Orally disintegrating pharmaceutical dosage form containing aripiprazole |
-
2013
- 2013-03-05 AR ARP130100712A patent/AR090245A1/es unknown
- 2013-03-05 TW TW102107618A patent/TW201343201A/zh unknown
- 2013-03-06 JP JP2014543382A patent/JP2015509482A/ja active Pending
- 2013-03-06 SG SG11201404915SA patent/SG11201404915SA/en unknown
- 2013-03-06 MX MX2014010574A patent/MX2014010574A/es not_active Application Discontinuation
- 2013-03-06 EA EA201491640A patent/EA201491640A1/ru unknown
- 2013-03-06 CA CA2865882A patent/CA2865882A1/en not_active Abandoned
- 2013-03-06 CN CN201380013047.5A patent/CN104159949A/zh active Pending
- 2013-03-06 IN IN6939DEN2014 patent/IN2014DN06939A/en unknown
- 2013-03-06 US US14/383,401 patent/US20150037424A1/en not_active Abandoned
- 2013-03-06 WO PCT/JP2013/056881 patent/WO2013133448A1/en active Application Filing
- 2013-03-06 AU AU2013228315A patent/AU2013228315A1/en not_active Abandoned
- 2013-03-06 KR KR1020147027554A patent/KR20140131987A/ko not_active Application Discontinuation
- 2013-03-06 EP EP13712944.1A patent/EP2822989A1/en not_active Withdrawn
-
2014
- 2014-08-15 PH PH12014501853A patent/PH12014501853A1/en unknown
- 2014-10-06 CO CO14220343A patent/CO7091180A2/es unknown
-
2015
- 2015-02-10 HK HK15101485.3A patent/HK1200738A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2865882A1 (en) | 2013-09-12 |
| JP2015509482A (ja) | 2015-03-30 |
| KR20140131987A (ko) | 2014-11-14 |
| HK1200738A1 (en) | 2015-08-14 |
| CN104159949A (zh) | 2014-11-19 |
| CO7091180A2 (es) | 2014-10-21 |
| IN2014DN06939A (es) | 2015-04-10 |
| US20150037424A1 (en) | 2015-02-05 |
| PH12014501853A1 (en) | 2014-11-17 |
| EA201491640A1 (ru) | 2015-01-30 |
| WO2013133448A1 (en) | 2013-09-12 |
| SG11201404915SA (en) | 2014-10-30 |
| EP2822989A1 (en) | 2015-01-14 |
| MX2014010574A (es) | 2014-12-08 |
| TW201343201A (zh) | 2013-11-01 |
| AU2013228315A1 (en) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170139A7 (es) | Derivados de ciclohexano sustituido con amido | |
| CL2017000287A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| AR099756A1 (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso, composición farmacéutica | |
| PE20150200A1 (es) | Formulacion de anticuerpos | |
| AR104984A1 (es) | Compuestos selectivos para pyy y sus usos | |
| CL2014003509A1 (es) | Composición veterinaria masticable blanda que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal (div. sol. n°2087-14). | |
| BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
| BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
| UY35298A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| PE20150731A1 (es) | Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso | |
| UY35301A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| AR081015A1 (es) | Formulaciones de galactomananos oftalmicas estabilizadas. metodo. | |
| NI201600006A (es) | Pirazolo-piridinaminas sustituidas | |
| UY35848A (es) | Tienopirimidinas | |
| PE20151066A1 (es) | Dispersion solida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| AR091039A1 (es) | Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento | |
| ES2613698T3 (es) | Combinación, kit y método de reducción de la presión intraocular | |
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| BR112017025395A2 (pt) | formulações farmacêuticas para liberação prolongada de sebacoil éster de dinalbufina | |
| AR090245A1 (es) | Preparacion solida oral de liberacion sostenida, metodo de preparacion | |
| BR112013019924A8 (pt) | Composições para cuidado oral | |
| PE20151300A1 (es) | Composicion antifungica topica para el tratamiento de onicomicosis | |
| WO2012119102A3 (en) | Homeopathic therapeutic method and compositions | |
| CR20140355A (es) | Formulaciones de antibióticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |